Download PDF
Semin Thromb Hemost 2001; 27(6): 639-652
DOI: 10.1055/s-2001-18868
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Regulatory Role of Cytokines in Disseminated Intravascular Coagulation

Tom van der Poll1,2 , Evert de Jonge3 , Marcel Levi4
  • 1Laboratory of Experimental Internal Medicine, , Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • 2Department of Infectious Diseases, Tropical Medicine and AIDS, , Academic Medical Center, University of Amsterdam, Amsterdam, The Netherland
  • 3Department of Intensive Care Medicine, , Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and the
  • 4Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
06 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Disseminated intravascular coagulation (DIC) can complicate a number of diseases. DIC in the setting of sepsis is considered to result from strong activation of the coagulation system and concurrent inhibition of fibrinolysis and other anticoagulant pathways. Cytokines have been implicated as important mediators in these hemostatic alterations. This article summarizes recent insights into which cytokines are likely to be involved in the procoagulant response to systemic infection.

KEYWORD

Cytokines - endotoxin - coagulation - fibrinolysis - protein C

REFERENCES

  • 1 Hack C E, Aarden L A, Thijs L G. Role of cytokines in sepsis.  Adv Immunol . 1997;  66 101-195
    PubMedGoogle Scholar
  • 2 van der Poll T, van Deventer J H S. Cytokines and anti-cytokines in the pathogenesis of sepsis.  Infect Dis Clin North Am . 1999;  13 413-426
    CrossrefPubMedGoogle Scholar
  • 3 Lowry S F, Calvano S E, van der Poll T. Measurement of inflammatory mediators in clinical sepsis. In: Sibbald WJ, Vincent JL, eds. Clinical Trials for the Treatment of Sepsis New York: Springer 1995: 86-105
    Google Scholar
  • 4 Dehoux M S, Boutten A, Ostinelli J. Compartimentalized cytokine production within the human lung in unilateral pneumonia.  Am J Respir Crit Care Med . 1994;  150 710-716
    PubMedGoogle Scholar
  • 5 Fröhlich D, Eiber R M, Jochum M, Billing A. Perioperative pattern of peritoneal interleukin 8, tumour necrosis factor-α, and granulocyte elastase release in human secondary peritonitis.  Cytokine . 1997;  9 288-292
    CrossrefPubMedGoogle Scholar
  • 6 Olszyna D P, Prins J M, Buis B. Levels of inhibitors of tumor necrosis factor-α and interleukin 1 in urine and sera of patients with urosepsis.  Infect Immun . 1998;  66 3527-3534
    PubMedGoogle Scholar
  • 7 Marchant A, Deviere J, Byl B. Interleukin-10 production during septicaemia.  Lancet . 1994;  343 707-710
    CrossrefPubMedGoogle Scholar
  • 8 van der Poll T, de Waal Malefyt R, Coyle S M, Lowry S F. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10 and IL-13 concentrations.  J Infect Dis . 1997;  175 118-122
    PubMedGoogle Scholar
  • 9 van Zee J K, Kohno T, Fischer E. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo.  Proc Natl Acad Sci USA . 1992;  89 4845-4849
    PubMedGoogle Scholar
  • 10 Fong Y, Tracey K J, Moldawer L L. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia.  J Exp Med . 1989;  170 1627-1633
    CrossrefPubMedGoogle Scholar
  • 11 van der Poll T, van Deventer J H S. Endotoxemia in healthy subjects as a human model of inflammation. In: Cohen J, Marshall J, eds. The Immune Response in the Critically Ill New York: Springer 1999: 335-357
    Google Scholar
  • 12 van der Poll T, Levi M, van Deventer J H S. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees.  Blood . 1994;  83 446-451
    PubMedGoogle Scholar
  • 13 van der Poll T, Coyle S M, Levi M. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans.  Blood . 1997;  89 3727-3734
    PubMedGoogle Scholar
  • 14 van der Poll T, Jansen J, Levi M. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees.  J Exp Med . 1994;  180 1985-1988
    CrossrefPubMedGoogle Scholar
  • 15 Jansen P M, van der Pouw Kraan T C T M, de Jong W I. Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: Relation to plasma levels of interleukin-10 and interferon-γ.  Blood . 1996;  87 5144-5151
    PubMedGoogle Scholar
  • 16 Jansen J, van der Poll T, Levi M. Inhibition of the release of soluble tumour necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-α antibody.  J Clin Immunol . 1995;  15 45-50
    CrossrefPubMedGoogle Scholar
  • 17 Tracey K J, Beutler B, Lowry S F. Shock and tissue injury induced by recombinant human cachectin.  Science . 1986;  234 470-474
    PubMedGoogle Scholar
  • 18 Okusawa S, Gelfland J A, Ikejima T, Connolly R J, Dinarello C A. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.  J Clin Invest . 1988;  81 1162-1172
    PubMedGoogle Scholar
  • 19 Leonard J P, Sherman M L, Fisher G L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production.  Blood . 1997;  90 2541-2548
    PubMedGoogle Scholar
  • 20 Van Gameren M M, Willemse P HB, Mulder N H. Effects of recombinant human interleukin-6 in cancer patients: A phase I/II study.  Blood . 1994;  84 1434-1441
    PubMedGoogle Scholar
  • 21 Stouthard J ML, Romijn J A, van der Poll T. Endocrine and metabolic effects of interleukin-6 in humans.  Am J Physiol . 1995;  268 E813-E819
    PubMedGoogle Scholar
  • 22 Preiser J C, Schmartz D, van der Linden P. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog.  Cytokine . 1991;  3 1-4
    CrossrefPubMedGoogle Scholar
  • 23 Tracey K J, Fong Y, Hesse D G. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.  Nature . 1987;  330 662-664
    CrossrefPubMedGoogle Scholar
  • 24 Hinshaw L B, Tekamp-Olson P, Chang A CK. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF).  Circ Shock . 1990;  30 279-292
    PubMedGoogle Scholar
  • 25 Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson R C. Interleukin 1 receptor antagonist reduces mortality from endotoxin shock.  Nature . 1990;  348 550-552
    CrossrefPubMedGoogle Scholar
  • 26 Fischer E, Marano M A, Van Zee J K. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.  J Clin Invest . 1992;  89 1551-1557
    PubMedGoogle Scholar
  • 27 Fattori E, Cappelletti M, Costa P. Defective inflammatory response in interleukin-6-deficient mice.  J Exp Med . 1994;  180 1243-1250
    CrossrefPubMedGoogle Scholar
  • 28 Silva A T, Cohen J. Role of interferon-γ in experimental gram-negative sepsis.  J Infect Dis . 1992;  166 331-335
    PubMedGoogle Scholar
  • 29 Wysocka M, Kubin M, Vieira L Q. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice.  Eur J Immunol . 1995;  25 672-676
    PubMedGoogle Scholar
  • 30 Car B D, Eng V M, Schnyder B. Interferon-γ receptor deficient mice are resistant to endotoxic shock.  J Exp Med . 1994;  179 1437-1444
    CrossrefPubMedGoogle Scholar
  • 31 Berg D J, Kühn R, Rajewsky K. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.  J Clin Invest . 1995;  96 2339-2347
    PubMedGoogle Scholar
  • 32 Marchant A, Bruyns C, Vandenabeele P. IL-10 controls IFN-γ and TNF production during experimental endotoxemia.  Eur J Immunol . 1994;  24 1167-1171
    PubMedGoogle Scholar
  • 33 Muchamuel T, Menon S, Pisacane P, Howard M C, Cockayne D A. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-α, IFN-γ, and IL-12 production.  J Immunol . 1997;  158 2898-2903
    PubMedGoogle Scholar
  • 34 Levi M, ten Cate H. Disseminated intravascular coagulation.  N Engl J Med . 1999;  341 586-592
    CrossrefPubMedGoogle Scholar
  • 35 Østerud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infections related to unfavourable prognosis.  Thromb Haemost . 1983;  49 5-7
    PubMedGoogle Scholar
  • 36 Li A, Chang A C, Peer G T, Hinshaw L B, Taylor Jr B F. Comparison of the capacity of rhTNF-alpha and Escherichia coli to induce procoagulant activity by baboon mononuclear cells in vivo and in vitro.  Shock . 1996;  5 274-279
    PubMedGoogle Scholar
  • 37 Taylor Jr B F, Chang A, Ruf W. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody.  Circ Shock . 1991;  33 127-134
    PubMedGoogle Scholar
  • 38 Levi M, ten Cate H, Bauer K A. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.  J Clin Invest . 1994;  93 114-120
    CrossrefPubMedGoogle Scholar
  • 39 Biemond B J, ten Cate H, Levi M. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa.  Thromb Haemost . 1995;  73 223-230
    PubMedGoogle Scholar
  • 40 Taylor Jr B F, Chang A CK, Peer G, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli Blood .  1998;  91 1609-1615
    PubMedGoogle Scholar
  • 41 Creasey A A, Chang A CK, Feigen L. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.  J Clin Invest . 1993;  91 2850-2860
    CrossrefPubMedGoogle Scholar
  • 42 Carr C, Bild G S, Chang A CK. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock.  Circ Shock . 1995;  44 126-137
    PubMedGoogle Scholar
  • 43 De Jonge E, Dekkers P EP, Creasey A A. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and the cytokine response during human endotoxemia.  Blood . 2000;  95 1124-1129
    PubMedGoogle Scholar
  • 44 Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor.  J Exp Med . 1986;  163 740-745
    CrossrefPubMedGoogle Scholar
  • 45 Nawroth P P, Handley D A, Esmon C T, Stern D M. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity.  Proc Natl Acad Sci USA . 1986;  83 3460-3464
    PubMedGoogle Scholar
  • 46 Scarpati E M, Sadler J E. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor.  J Biol Chem . 1989;  264 20705-20713
    PubMedGoogle Scholar
  • 47 Conckling P R, Greenberg C S, Weinberg J B. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes.  Blood . 1988;  72 128-133
    PubMedGoogle Scholar
  • 48 Herbert J M, Savi P, Laplace M C, Lale A. IL-4 inhibits LPS-, IL-1β- and TNFα-induced expression of tissue factor in endothelial cells and monocytes.  FEBS Lett . 1992;  310 31-33
    CrossrefPubMedGoogle Scholar
  • 49 Herbert J M, Savi P, Laplace M C. IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes.  FEBS Lett . 1993;  328 268-270
    CrossrefPubMedGoogle Scholar
  • 50 Martin N B, Jamieson A, Tuffin D P. The effect of interleukin-4 on tumour necrosis factor-alpha induced expression of tissue factor and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells.  Thromb Haemost . 1993;  70 1037-1042
    PubMedGoogle Scholar
  • 51 Schwager I, Jungi T W. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity.  Blood . 1994;  83 152-160
    PubMedGoogle Scholar
  • 52 Kirchhofer D, Tschopp T B, Hadvary P, Baumgartner H R. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors.  J Clin Invest . 1994;  93 2073-2083
    PubMedGoogle Scholar
  • 53 Paleolog E M, Delasalle S AJ, Buurman W A, Feldmann M. Functional activities of receptors for tumor necrosis factor-a on human vascular endothelial cells.  Blood . 1994;  84 2578-2590
    PubMedGoogle Scholar
  • 54 Schmid E F, Binder K, Grell M, Scheurich P, Pfizenmaier K. Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtracrine tumor necrosis factor alpha.  Blood . 1995;  86 1836-1841
    PubMedGoogle Scholar
  • 55 Del Prete G, de Carli M, Lammel R M. Th1 and Th2 T-helper cells exert opposite effects on procoagulant activity and tissue factor production by human monocytes.  Blood . 1995;  86 250-257
    PubMedGoogle Scholar
  • 56 Osnes L T, Westvik A B, Joo G B, Okkenhaug C, Kierulf P. Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13.  Cytokine . 1996;  8 822-827
    CrossrefPubMedGoogle Scholar
  • 57 Ernofsson M, Tenno T, Siegbahn A. Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines.  Br J Haematol . 1996;  95 249-257
    CrossrefPubMedGoogle Scholar
  • 58 Schecter A D, Rollins B J, Zhang Y J. Tissue factor induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells.  J Biol Chem . 1997;  272 28568-28573
    CrossrefPubMedGoogle Scholar
  • 59 Neumann F J, Ott I, Marx N. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity.  Arterioscler Thromb Vasc Biol . 1997;  17 3399-3405
    CrossrefPubMedGoogle Scholar
  • 60 Meisel S R, Shimon I, Edgington T S. Leukemia inhibitory factor enhances tissue factor expression in human monocyte-derived macrophages: A gp130-mediated mechanism.  Br J Haematol . 1999;  107 747-755
    CrossrefPubMedGoogle Scholar
  • 61 Veltrop M H, Beekhuizen H, Thompson J. Bacterial species- and strain-dependent induction of tissue factor in human vascular endothelial cells.  Infect Immun . 1999;  67 6130-6138
    PubMedGoogle Scholar
  • 62 Pradier O, Gérard C, Delvaux A. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide.  Eur J Immunol . 1993;  23 2700-2703
    PubMedGoogle Scholar
  • 63 Ramani M, Khechai F, Ollivier V. Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes.  FEBS Lett . 1994;  356 86-88
    CrossrefPubMedGoogle Scholar
  • 64 Wharram B L, Fitting K, Kunkel S L. Tissue factor expression in endothelial cell/monocyte cocultures stimulated by lipopolysaccharide and/or aggregated IgG. Mechanisms of cell:cell communication.  J Immunol . 1991;  146 1437-1445
    PubMedGoogle Scholar
  • 65 Lo S K, Cheung A, Zheng Q, Silverstein R L. Induction of tissue factor on monocytes by adhesion to endothelial cells.  J Immunol . 1995;  154 4768-4777
    PubMedGoogle Scholar
  • 66 van der Poll T, Büller H R, ten Cate H. Activation of coagulation after administration of tumor necrosis factor to normal subjects.  N Engl J Med . 1990;  322 1622-1627
    CrossrefPubMedGoogle Scholar
  • 67 Bauer K A, ten Cate H, Barzegar S. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans.  Blood . 1989;  74 165-172
    PubMedGoogle Scholar
  • 68 van der Poll T, Jansen P M, van Zee J K. Tumor necrosis factor induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor.  Blood . 1996;  88 922-927
    PubMedGoogle Scholar
  • 69 DeLa Cadena A R, Majluf-Cruz A, Stadnicki A. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans.  Thromb Haemost . 1998;  80 114-118
    PubMedGoogle Scholar
  • 70 Jansen P M, Boermeester M A, Fischer E. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, to neutrophil degranulation and the release of sPLA2 in sepsis. Studies in non-human primates following interleukin-1 administration and during lethal bacteremia.  Blood . 1995;  86 1027-1034
    PubMedGoogle Scholar
  • 71 Stouthard J ML, Levi M, Hack C E. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans.  Thromb Haemost . 1996;  76 738-742
    PubMedGoogle Scholar
  • 72 van der Poll T, Levi M, Hack C E. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.  J Exp Med . 1994;  179 1253-1259
    CrossrefPubMedGoogle Scholar
  • 73 Lauw F N, Dekkers P EP, te Velde A A. Interleukin 12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees.  J Infect Dis . 1999;  179 646-652
    CrossrefPubMedGoogle Scholar
  • 74 Baars J W, de Boer P J, Wagstaff J. Interleukin-2 induces activation of coagulation and fibrinolysis: Resemblance to the changes seen during endotoxaemia.  Br J Haematol . 1992;  82 295-301
    CrossrefPubMedGoogle Scholar
  • 75 Pajkrt D, van der Poll T, Levi M. Interleukin 10 inhibits activation of coagulation and fibrinolysis during human endotoxemia.  Blood . 1997;  89 2701-2705
    PubMedGoogle Scholar
  • 76 van der Poll T, Jansen P M, Montegut W J. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia.  J Immunol . 1997;  158 1971-1975
    PubMedGoogle Scholar
  • 77 Esmon C T. New potential therapeutic modalities: APC.  Sepsis . 1999;  3 161-172
    CrossrefPubMedGoogle Scholar
  • 78 Stearns-Kurosawa D J, Kurosawa S, Mollica J S, Ferrell G L, Esmon C T. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex.  Proc Natl Acad Sci USA . 1996;  93 10212-10216
    CrossrefPubMedGoogle Scholar
  • 79 Regan L M, Stearns-Kurosawa D J, Kurosawa S. The endothelial cell protein C receptor: Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors.  J Biol Chem . 1996;  271 17499-17503
    CrossrefPubMedGoogle Scholar
  • 80 Taylor Jr B F, Chang A, Esmon T. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.  J Clin Invest . 1987;  79 918-925
    CrossrefPubMedGoogle Scholar
  • 81 Taylor Jr B F, Stearns-Kurosawa J, Kurosawa S. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis.  Blood . 2000;  95 1680-1686
    PubMedGoogle Scholar
  • 82 Taylor Jr B F, Chang A, Ferrell G. C4b-binding protein exacerbates the host response to Escherichia coli Blood .  1991;  78 357-363
    PubMedGoogle Scholar
  • 83 Lentz S R, Tsiang M, Sadler J E. Regulation of thrombomodulin by tumor necrosis factor-α: comparison of transcriptional and posttranscriptional mechanism.  Blood . 1991;  77 542-550
    PubMedGoogle Scholar
  • 84 Grey S T, Csizmadia V, Hancock W W. Differential effect of tumor necrosis factor-α on thrombomodulin gene expression by human monocytoid (THP-1) cells versus endothelial cells.  Int J Hematol . 1998;  67 53-62
    PubMedGoogle Scholar
  • 85 Raife T J, Demetroulis E M, Lentz S R. Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor-α: differential responses in keratinocytes and endothelial cells.  Blood . 1996;  88 2043-2049
    PubMedGoogle Scholar
  • 86 Fukudome K, Esmon C T. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor.  J Biol Chem . 1994;  269 26486-26491
    PubMedGoogle Scholar
  • 87 Xu J, Qu D, Esmon N L, Esmon C T. Metalloproteolytic release of endothelial cell protein C receptor.  J Biol Chem . 2000;  275 6038-6044
    CrossrefPubMedGoogle Scholar
  • 88 Redl H, Schlag G, Schiesser A, Davies J. Thrombomodulin release in baboon sepsis: its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor.  J Infect Dis . 1995;  171 1522-1527
    PubMedGoogle Scholar
  • 89 Yamamoto K, Shimokawa T, Kojima T, Loskutoff D J, Saito H. Regulation of murine protein C gene expression in vivo: effects of tumor necrosis factor-α, interleukin-1 and transforming growth factor-β.  Thromb Haemost . 1999;  82 1297-1301
    PubMedGoogle Scholar
  • 90 De Boer P J, Creasy A A, Chang A. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli Circ Shock .  1993;  39 59-67
    PubMedGoogle Scholar
  • 91 Schleef R R, Bevilaqua M P, Sawdey M, Gimbrone Jr A M, Loskutoff D J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.  J Biol Chem . 1988;  263 5797-5803
    PubMedGoogle Scholar
  • 92 Sawdey M, Podor T J, Loskutoff D J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-β, lipopolysaccharide, and tumor necrosis factor-α.  J Biol Chem . 1989;  264 10396-10401
    PubMedGoogle Scholar
  • 93 van Hinsbergh W V, van den Berg A E, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.  Blood . 1990;  75 1991-1998
    PubMedGoogle Scholar
  • 94 Gallicchio M, Hufnagl P, Wojta J, Tipping P. IFN-γ inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells.  J Immunol . 1996;  157 2610-2617
    PubMedGoogle Scholar
  • 95 Arnman V, Stemme S, Rymo L, Risberg B. Interferon-γ modulates the fibrinolytic response in cultured human endothelial cells.  Thromb Res . 1995;  77 431-440
    CrossrefPubMedGoogle Scholar
  • 96 Takahashi K, Uwabe Y, Sawasaki Y. Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells.  Am J Physiol . 1998;  275 L47-L54
    PubMedGoogle Scholar
  • 97 Niedbala M J, Picarella M S. Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon.  Blood . 1992;  79 678-687
    PubMedGoogle Scholar
  • 98 Wojta J, Gallicchio M, Zoellner H. Interleukin-4 stimulates expression of urokinase-type-plasminogen activator in cultured human foreskin microvascular endothelial cells.  Blood . 1993;  81 3285-3292
    PubMedGoogle Scholar
  • 99 De Boer P J, Abbink J J, Brouwer M C. PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines. Evidence that the liver contributes to acute phase behaviour of PAI-1.  Thromb Haemost . 1991;  65 181-185
    PubMedGoogle Scholar
  • 100 Healy A M, Gelehrter T D. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response.  J Biol Chem . 1994;  269 19095-19100
    PubMedGoogle Scholar
  • 101 Seki T, Gelehrter T D. Interleukin-1 induction of type-1 plasminogen activator inhibitor (PAI-1) gene expression in the mouse hepatocyte line, AML 12.  J Cell Physiol . 1996;  168 648-656
    CrossrefPubMedGoogle Scholar
  • 102 Busso N, Nicodeme E, Chesne C. Urokinase and type 1 plasminogen activator inhibitor production by normal hepatocytes: modulation by inflammatory agents.  Hepatology . 1994;  20 189-190
    PubMedGoogle Scholar
  • 103 Suffredini A F, Harpel P C, Parrillo J E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.  N Engl J Med . 1989;  320 1165-1172
    CrossrefPubMedGoogle Scholar
  • 104 van der Poll T, Levi M, Büller H R. Fibrinolytic response to tumor necrosis factor in healthy subjects.  J Exp Med . 1991;  174 729-732
    CrossrefPubMedGoogle Scholar
  • 105 van Hinsbergh W V, Bauer K A, Kooistra T. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.  Blood . 1990;  76 2284-2289
    PubMedGoogle Scholar
  • 106 Logan T F, Virji M A, Gooding W E. Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor.  J Natl Cancer Inst . 1992;  84 1802-1810
    PubMedGoogle Scholar
  • 107 Fearns C, Loskutoff D J. Induction of plasminogen activator inhibitor type 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-α.  Am J Pathol . 1997;  150 579-590
    PubMedGoogle Scholar
  • 108 Seki T, Healy A M, Fletcher D S, Noguchi T, Gelehrter T D. IL-1β mediates induction of hepatic type I plasminogen activator inhibitor in response to local tissue injury.  Am J Physiol . 1999;  277 G801-G809
    PubMedGoogle Scholar
  • 109 Mileno M D, Margolis N H, Clark B D. Coagulation of whole blood stimulates interleukin-1β gene expression.  J Infect Dis . 1995;  172 308-311
    PubMedGoogle Scholar
  • 110 Jones A, Geczy C L. Thrombin and factor Xa enhance the production of interleukin-1.  Immunology . 1990;  71 236-241
    PubMedGoogle Scholar
  • 111 Johnson K, Aarden L A, Choi Y, De Groot E, Creasey A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood.  Blood . 1996;  87 5051-5060
    PubMedGoogle Scholar
  • 112 Johnson K, Choi Y, De Groot E. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation.  J Immunol . 1998;  160 5130-5135
    PubMedGoogle Scholar
  • 113 Suk K, Cha S H. Thrombin-induced interleukin-8 production and its regulation by interferon-γ and prostaglandin E2 in human monocytic U937 cells.  Immunol Lett . 1999;  67 223-227
    CrossrefPubMedGoogle Scholar
  • 114 Sower L E, Froelich C J, Fenton J W, Klimpel G R. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha thrombin.  J Immunol . 1995;  155 895-901
    PubMedGoogle Scholar
  • 115 Qi J, Goralnick S, Kreutzer D L. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells.  Blood . 1997;  90 3595-3602
    PubMedGoogle Scholar
  • 116 Senden N MH, Jeunhomme T A A M, Heemskerk J WM. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells.  J Immunol . 1998;  161 4318-4324
    PubMedGoogle Scholar
  • 117 Ueno A, Murakami K, Yamanouchi K, Watanabe M, Kondo T. Thrombin stimulates production of interleukin-8 in human endothelial cells.  Immunology . 1996;  88 76-81
    CrossrefPubMedGoogle Scholar
  • 118 Anrather D, Millan M T, Palmetshofer A. Thrombin activates nuclear factor-κB and potentiates endothelial cell activation by TNF.  J Immunol . 1997;  159 5620-5628
    PubMedGoogle Scholar
  • 119 Hancock W W, Tsuchida A, Hau H, Thomson N M, Salem H H. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy.  Transplant Proc . 1992;  24 2302-2303
    PubMedGoogle Scholar
  • 120 Grey S T, Tsuchida A, Hau H. Selective inhibitor effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-γ, or phorbol ester.  J Immunol . 1994;  153 3664-3672
    PubMedGoogle Scholar
  • 121 Murakami K, Okajima K, Uchiba M. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.  Blood . 1996;  87 642-647
    PubMedGoogle Scholar
  • 122 Hancock W W, Bach F H. Immunobiology and therapeutic applications of protein C/protein S/thrombomodulin in human and experimental allotransplantation and xenotransplantation.  Trends Cardiovasc Med . 1997;  7 174-183
    CrossrefPubMedGoogle Scholar
  • 123 Hooper W C, Phillips D J, Renshaw M A, Evatt B L, Benson J M. The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C.  J Immunol . 1998;  161 2567-2573
    PubMedGoogle Scholar
  • 124 Robson S C, Saunders R, Kirsch R E. Monocyte-macrophage release of IL-1 is inhibited by type-1 plasminogen activator inhibitor.  J Clin Lab Immunol . 1990;  33 83-90
    PubMedGoogle Scholar
  • 125 Sitrin R G, Shollenberger S B, Strieter R M, Gyetko M R. Endogenously produced urokinase amplifies tumor necrosis factor-α secretion by THP-1 mononuclear phagocytes.  J Leukoc Biol . 1996;  59 302-311
    PubMedGoogle Scholar
  • 126 Parmely M J, Sterner K E, Gale A, Zhou W W. U937 cells can utilize plasminogen activator to regulate human interferon-γ.  J Interferon Res . 1993;  13 397-406
    PubMedGoogle Scholar
  • 127 Taylor Jr B F, Chang A CK, Peer G T. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage.  Blood . 1991;  78 364-368
    PubMedGoogle Scholar
  • 128 Uchiba M, Okajima K, Murakami K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.  Thromb Haemost . 1995;  74 1265-1270
    PubMedGoogle Scholar
  • 129 Taoka Y, Okajima K, Uchiba M. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes.  J Neurosci . 1998;  18 1393-1398
    PubMedGoogle Scholar